From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-span Approach to Bring New Drugs to Patients

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2015 Feb 12

PMID 25669457

Citations 60

Authors

H-G Eichler

L G Baird

R Barker

B Bloechl-Daum

F Borlum-Kristensen

J Brown

R Chua

S Del Signore

U Dugan

J Ferguson

S Garner

W Goettsch

J Haigh

P Honig

A Hoos

P Huckle

T Kondo

Y Le Cam

H Leufkens

R Lim

C Longson

M Lumpkin

J Maraganore

B ORourke

K Oye

E Pezalla

F Pignatti

J Raine

G Rasi

T Salmonson

D Samaha

S Schneeweiss

P D Siviero

M Skinner

J R Teagarden

T Tominaga

M R Trusheim

S Tunis

T F Unger

S Vamvakas

G Hirsch

Affiliations

Soon will be listed here.

Abstract

The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life-span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade-off, help de-risk drug development, and lead to better outcomes for patients.

Citing Articles

Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven.

Niazi S Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598336 PMC: 11597071. DOI: 10.3390/ph17111424.

Escalating costs of innovative medicines: perspective and proposals.

Vallano A, Pontes C Front Public Health. 2024; 12:1449707.

PMID: 39381757 PMC: 11458516. DOI: 10.3389/fpubh.2024.1449707.

Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens.

Radu P, Kumar G, Cole A, Fameli A, Guthrie M, Annemans L Oncologist. 2024; 29(6):465-472.

PMID: 38630538 PMC: 11144967. DOI: 10.1093/oncolo/oyae060.

Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data.

Heyard R, Held L, Schneeweiss S, Wang S BMJ Med. 2024; 3(1):e000709.

PMID: 38348308 PMC: 10860009. DOI: 10.1136/bmjmed-2023-000709.

RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study.

Bright K, Mills A, Bradford J, Stewart D Front Health Serv. 2023; 3:1015621.

PMID: 36926496 PMC: 10012713. DOI: 10.3389/frhs.2023.1015621.

References

Eichler H, Oye K, Baird L, Abadie E, Brown J, Drum C . Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012; 91(3):426-37. DOI: 10.1038/clpt.2011.345. View

Schlich T . Railways, industry, and surgery--the introduction of risk management. N Engl J Med. 2013; 369(21):1978-9. DOI: 10.1056/NEJMp1309194. View

Pimplikar S, Nixon R, Robakis N, Shen J, Tsai L . Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci. 2010; 30(45):14946-54. PMC: 3426835. DOI: 10.1523/JNEUROSCI.4305-10.2010. View

Trusheim M, Berndt E, Douglas F . Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007; 6(4):287-93. DOI: 10.1038/nrd2251. View

Johnston J, Feldschreiber P . Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products. Br J Clin Pharmacol. 2014; 77(6):939-46. PMC: 4093919. DOI: 10.1111/bcp.12250. View

Baird L, Banken R, Eichler H, Kristensen F, Lee D, Lim J . Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther. 2014; 96(5):559-71. DOI: 10.1038/clpt.2014.145. View

Coast J . Strategies for the economic evaluation of end-of-life care: making a case for the capability approach. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(4):473-82. DOI: 10.1586/14737167.2014.914436. View

Sleijfer S, Bogaerts J, Siu L . Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013; 31(15):1834-41. DOI: 10.1200/JCO.2012.45.3639. View

Selker H, Oye K, Eichler H, Stockbridge N, Mehta C, Kaitin K . A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther. 2013; 95(2):147-53. PMC: 3904553. DOI: 10.1038/clpt.2013.177. View

10.

Woodcock J . Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?. Clin Pharmacol Ther. 2012; 91(3):378-80. DOI: 10.1038/clpt.2011.337. View

11.

Eichler H, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J . The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013; 12(12):907-16. DOI: 10.1038/nrd4129. View

12.

Henshall C, Schuller T . Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013; 29(4):353-9. DOI: 10.1017/S0266462313000378. View

13.

Willyard C . 'Basket studies' will hold intricate data for cancer drug approvals. Nat Med. 2013; 19(6):655. DOI: 10.1038/nm0613-655. View

14.

Eichler H, Bloechl-Daum B, Abadie E, Barnett D, Konig F, Pearson S . Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010; 9(4):277-91. DOI: 10.1038/nrd3079. View

15.

Lievre A, Bachet J, Le Corre D, Boige V, Landi B, Emile J . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. DOI: 10.1158/0008-5472.CAN-06-0191. View

16.

Hara A, Sato D, Sahara Y . New Governmental Regulatory System for Stem Cell-Based Therapies in Japan. Ther Innov Regul Sci. 2018; 48(6):681-688. DOI: 10.1177/2168479014526877. View

17.

Fleurence R, Curtis L, Califf R, Platt R, Selby J, Brown J . Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014; 21(4):578-82. PMC: 4078292. DOI: 10.1136/amiajnl-2014-002747. View

18.

Kocher R, Roberts B . The calculus of cures. N Engl J Med. 2014; 370(16):1473-5. DOI: 10.1056/NEJMp1400868. View

19.

Kristensen F, Lampe K, Chase D, Lee-Robin S, Wild C, Moharra M . Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Int J Technol Assess Health Care. 2009; 25 Suppl 2:1-8. DOI: 10.1017/S0266462309990626. View

20.

Pike K, Savage G, Villemagne V, Ng S, Moss S, Maruff P . Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130(Pt 11):2837-44. DOI: 10.1093/brain/awm238. View